DM Corporation and ORF Genetics to Collaborate on Protein Drugs

An MOU Signed During Official Visit of Mrs. Preneet Kau, Indian Minister of State for External Affairs, to Iceland

06-Sep-2010 - Iceland

The Indian company DM Corporation and ORF genetics are to collaborate on the development, production and marketing of protein drugs. Mr. Dilip Mohite, Chairman and Managing Director of DM Corporation and Björn Örvar, CEO of ORF Genetics, signed an MOU to this effect.

The MOU states that the companies will form a joint venture to develop and market human recombinant therapeutic proteins and biosimilars. DM Corporation will bring to the collaboration expertise in management of pre-clinical research, clinical development and marketing. ORF Genetics will supply its expertise in plant genetics and protein biochemistry, including its proprietary Orfeus(TM) protein production system in genetically modified barley. The Orfeus (TM) platform was developed to produce high-quality recombinant proteins on a large scale, bypassing production in E. coli, yeast or mammalian cells.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances